NRX Pharmaceuticals Eyes $30M Refinancing and Funding Deal
Company Announcements

NRX Pharmaceuticals Eyes $30M Refinancing and Funding Deal

NRX Pharmaceuticals (NRXP) just unveiled an update.

A company has announced through a press release that it has agreed on a non-binding term sheet, which could provide up to $7.5 million to refinance existing toxic debt, with a potential for an extra $22.5 million in additional funding. The total accessible capital could reach $30 million, but this is contingent upon successful due diligence and the finalization of binding agreements.

For a thorough assessment of NRXP stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyNRx signs non-binding LOI to acquire Interventional Psychiatry Clinics
TheFlyNRx Pharmaceuticals initiated with a Buy at EF Hutton
TipRanks Auto-Generated NewsdeskNRx Pharmaceuticals Leadership Shift and Strategic Governance Decisions
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App